Biovica

Russia
Kholbon, Zabaykalskiy (Transbaikal) Kray, Russia, 752 37

Company profile

Biovica company profile

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum™ assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2009-01-01, Year

Headquarters

Postal code
752 37
Country code
RU
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$16M
Last funding
Post IPO Equity / $12.6M / 2025-08-05
Last equity funding
Post IPO Equity / $12.6M
Investors
1
Lead investors
1
Articles
50
Exited on
2017-03-29

Founders and investors

Lead investors

HDF Impact BV

Investors

HDF Impact BV